{
  "study_id": "NCT01244191",
  "study_title": "Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer",
  "table_name": "Table 1",
  "table_title": "Patient Baseline Demographic and Clinical Characteristics (ITT population)",
  "description": "Baseline demographic and clinical characteristics for the intent-to-treat (ITT) population.",
  "footnotes": [
    "Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ITT, intent to treat; NSCLC, non–small-cell lung cancer; SD, standard deviation."
  ],
  "groups": [
    {
      "name": "Erlotinib Plus Tivantinib",
      "n": 526,
      "type": "Intervention"
    },
    {
      "name": "Erlotinib Plus Placebo",
      "n": 522,
      "type": "Control"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age, years",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "Age, years"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "Age, years"
        }
      ]
    },
    {
      "original_label": "Mean",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "numeric_mean_sd",
          "mean": 61.2,
          "raw_string": "61.2"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "numeric_mean_sd",
          "mean": 61.1,
          "raw_string": "61.1"
        }
      ]
    },
    {
      "original_label": "SD",
      "standardized_name": "Age Standard Deviation",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "numeric_single",
          "value": 10.1,
          "raw_string": "10.1"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "numeric_single",
          "value": 9.8,
          "raw_string": "9.8"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "raw_string": "62.0"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "numeric_median_iqr",
          "median": 61.0,
          "raw_string": "61.0"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Age Range",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "numeric_mean_range",
          "range_min": 26.0,
          "range_max": 89.0,
          "raw_string": "26-89"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "numeric_mean_range",
          "range_min": 24.0,
          "range_max": 87.0,
          "raw_string": "24-87"
        }
      ]
    },
    {
      "original_label": "Sex",
      "standardized_name": "Sex",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "Sex"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "Sex"
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Sex",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 216.0,
          "percentage": 41.1,
          "raw_string": "216 (41.1)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 213.0,
          "percentage": 40.8,
          "raw_string": "213 (40.8)"
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Sex",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 310.0,
          "percentage": 58.9,
          "raw_string": "310 (58.9)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 309.0,
          "percentage": 59.2,
          "raw_string": "309 (59.2)"
        }
      ]
    },
    {
      "original_label": "Race",
      "standardized_name": "Race",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "Race"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "Race"
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 430.0,
          "percentage": 81.7,
          "raw_string": "430 (81.7)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 446.0,
          "percentage": 85.4,
          "raw_string": "446 (85.4)"
        }
      ]
    },
    {
      "original_label": "Black",
      "standardized_name": "Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 3.0,
          "raw_string": "16 (3.0)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 2.3,
          "raw_string": "12 (2.3)"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 1.5,
          "raw_string": "8 (1.5)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 1.0,
          "raw_string": "5 (1.0)"
        }
      ]
    },
    {
      "original_label": "Other or not reported",
      "standardized_name": "Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 71.0,
          "percentage": 13.5,
          "raw_string": "71 (13.5)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 59.0,
          "percentage": 11.3,
          "raw_string": "59 (11.3)"
        }
      ]
    },
    {
      "original_label": "Smoker",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "Smoker"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "Smoker"
        }
      ]
    },
    {
      "original_label": "Never",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoker",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 101.0,
          "percentage": 19.2,
          "raw_string": "101 (19.2)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 98.0,
          "percentage": 18.8,
          "raw_string": "98 (18.8)"
        }
      ]
    },
    {
      "original_label": "Ever",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoker",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 425.0,
          "percentage": 80.8,
          "raw_string": "425 (80.8)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 424.0,
          "percentage": 81.2,
          "raw_string": "424 (81.2)"
        }
      ]
    },
    {
      "original_label": "Current",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoker",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 98.0,
          "percentage": 18.6,
          "raw_string": "98 (18.6)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 97.0,
          "percentage": 18.6,
          "raw_string": "97 (18.6)"
        }
      ]
    },
    {
      "original_label": "Former",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoker",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 327.0,
          "percentage": 62.2,
          "raw_string": "327 (62.2)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 327.0,
          "percentage": 62.6,
          "raw_string": "327 (62.6)"
        }
      ]
    },
    {
      "original_label": "ECOG PS",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "ECOG PS"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "ECOG PS"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 168.0,
          "percentage": 31.9,
          "raw_string": "168 (31.9)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 168.0,
          "percentage": 32.2,
          "raw_string": "168 (32.2)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 357.0,
          "percentage": 67.9,
          "raw_string": "357 (67.9)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 353.0,
          "percentage": 67.6,
          "raw_string": "353 (67.6)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 (0.2)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 (0.2)"
        }
      ]
    },
    {
      "original_label": "Tumor stage at study entry",
      "standardized_name": "Tumor Stage",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "Tumor stage at study entry"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "Tumor stage at study entry"
        }
      ]
    },
    {
      "original_label": "IIIb",
      "standardized_name": "Tumor Stage",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage at study entry",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 22.0,
          "percentage": 4.2,
          "raw_string": "22 (4.2)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 2.7,
          "raw_string": "14 (2.7)"
        }
      ]
    },
    {
      "original_label": "IV",
      "standardized_name": "Tumor Stage",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage at study entry",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 499.0,
          "percentage": 94.9,
          "raw_string": "499 (94.9)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 501.0,
          "percentage": 96.0,
          "raw_string": "501 (96.0)"
        }
      ]
    },
    {
      "original_label": "Not reported",
      "standardized_name": "Tumor Stage",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage at study entry",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 1.0,
          "raw_string": "5 (1.0)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 1.3,
          "raw_string": "7 (1.3)"
        }
      ]
    },
    {
      "original_label": "NSCLC histologic type",
      "standardized_name": "NSCLC Histologic Type",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "NSCLC histologic type"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "NSCLC histologic type"
        }
      ]
    },
    {
      "original_label": "Adenocarcinoma",
      "standardized_name": "NSCLC Histologic Type",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "NSCLC histologic type",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 480.0,
          "percentage": 91.3,
          "raw_string": "480 (91.3)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 495.0,
          "percentage": 94.8,
          "raw_string": "495 (94.8)"
        }
      ]
    },
    {
      "original_label": "Large-cell carcinoma",
      "standardized_name": "NSCLC Histologic Type",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "NSCLC histologic type",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 5.9,
          "raw_string": "31 (5.9)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 3.8,
          "raw_string": "20 (3.8)"
        }
      ]
    },
    {
      "original_label": "Other nonadenocarcinoma",
      "standardized_name": "NSCLC Histologic Type",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "NSCLC histologic type",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 15.0,
          "percentage": 2.8,
          "raw_string": "15 (2.8)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 1.4,
          "raw_string": "7 (1.4)"
        }
      ]
    },
    {
      "original_label": "Unclassified nonadenocarcinoma",
      "standardized_name": "NSCLC Histologic Type",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "NSCLC histologic type",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 1.3,
          "raw_string": "7 (1.3)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.6,
          "raw_string": "3 (0.6)"
        }
      ]
    },
    {
      "original_label": "Prior NSCLC radiotherapy",
      "standardized_name": "Prior NSCLC Radiotherapy",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "Prior NSCLC radiotherapy"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "Prior NSCLC radiotherapy"
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Prior NSCLC Radiotherapy",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior NSCLC radiotherapy",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 232.0,
          "percentage": 44.1,
          "raw_string": "232 (44.1)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 219.0,
          "percentage": 42.0,
          "raw_string": "219 (42.0)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Prior NSCLC Radiotherapy",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior NSCLC radiotherapy",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 294.0,
          "percentage": 55.9,
          "raw_string": "294 (55.9)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 303.0,
          "percentage": 58.0,
          "raw_string": "303 (58.0)"
        }
      ]
    },
    {
      "original_label": "Prior NSCLC surgery",
      "standardized_name": "Prior NSCLC Surgery",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "Prior NSCLC surgery"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "Prior NSCLC surgery"
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Prior NSCLC Surgery",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior NSCLC surgery",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 238.0,
          "percentage": 45.2,
          "raw_string": "238 (45.2)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 253.0,
          "percentage": 48.5,
          "raw_string": "253 (48.5)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Prior NSCLC Surgery",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior NSCLC surgery",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 288.0,
          "percentage": 54.8,
          "raw_string": "288 (54.8)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 269.0,
          "percentage": 51.5,
          "raw_string": "269 (51.5)"
        }
      ]
    },
    {
      "original_label": "No. of prior NSCLC systemic therapies",
      "standardized_name": "Number of Prior Systemic Therapies",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "header",
          "raw_string": "No. of prior NSCLC systemic therapies"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "header",
          "raw_string": "No. of prior NSCLC systemic therapies"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "Number of Prior Systemic Therapies",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "No. of prior NSCLC systemic therapies",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 346.0,
          "percentage": 65.8,
          "raw_string": "346 (65.8)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 348.0,
          "percentage": 66.7,
          "raw_string": "348 (66.7)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Number of Prior Systemic Therapies",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "No. of prior NSCLC systemic therapies",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 180.0,
          "percentage": 34.2,
          "raw_string": "180 (34.2)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 174.0,
          "percentage": 33.3,
          "raw_string": "174 (33.3)"
        }
      ]
    },
    {
      "original_label": "Brain metastases",
      "standardized_name": "Brain Metastases",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib Plus Tivantinib",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 12.5,
          "raw_string": "66 (12.5)"
        },
        {
          "group_name": "Erlotinib Plus Placebo",
          "data_type": "categorical_count_percentage",
          "count": 80.0,
          "percentage": 15.3,
          "raw_string": "80 (15.3)"
        }
      ]
    }
  ]
}